Related Experiment Video

Updated: May 20, 2026

Purification of Ubiquitinated p53 Proteins from Mammalian Cells
10:55

Purification of Ubiquitinated p53 Proteins from Mammalian Cells

Published on: March 21, 2022

TRIAD1 inhibits MDM2-mediated p53 ubiquitination and degradation

Seunghee Bae1, Jin Hyuk Jung, Karam Kim

  • 1Molecular-Targeted Drug Research Centre, Konkuk University, Seoul, Republic of Korea.

FEBS Letters
|July 24, 2012
PubMed

Insights

TRIAD1 activates the tumor suppressor protein 53 (p53) by inhibiting MDM2-mediated degradation. This discovery reveals TRIAD1 as a novel regulator of the p53-MDM2 pathway, crucial in cancer development.

Area of Science:

  • Molecular Biology
  • Cancer Biology
  • Biochemistry

Background:

  • Murine double minute 2 (MDM2) is an E3 ligase targeting tumor suppressor protein 53 (p53) for degradation.
  • The p53-MDM2 pathway is a critical regulator of tumorigenesis.
  • Understanding novel regulators of this axis is vital for cancer research.

Purpose of the Study:

  • To identify and characterize novel modulators of the p53-MDM2 interaction.
  • To investigate the role of TRIAD1 in regulating p53 stability and activity.
  • To elucidate the mechanism by which TRIAD1 affects p53-MDM2 signaling.

Main Methods:

  • Gene ablation and ectopic expression of TRIAD1 in cellular models.
  • Western blotting to assess p53 and MDM2 protein levels.
  • Immunoprecipitation assays to study protein-protein interactions.
  • Ubiquitination assays to quantify p53 modification.

Main Results:

  • Ablation of TRIAD1 reduces p53 levels and activity following DNA damage.
  • Ectopic TRIAD1 expression enhances p53 stability by inhibiting MDM2-mediated ubiquitination.
  • TRIAD1 directly binds to the C-terminus of p53, promoting its dissociation from MDM2.
  • TRIAD1 acts as a novel inhibitor of MDM2-mediated p53 degradation.

Conclusions:

  • TRIAD1 is a novel regulator of the p53-MDM2 axis.
  • TRIAD1 promotes p53 activation by interfering with MDM2 binding and degradation.
  • These findings identify TRIAD1 as a potential therapeutic target in cancers driven by p53 dysregulation.

More Related Videos

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

Detection of Protein Ubiquitination09:00

Detection of Protein Ubiquitination

Published on: August 19, 2009

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...